In plain English
A pharmacopoeia is an official book of quality rules for medicines and their ingredients [1].
Most of the book is made of monographs. A monograph is a set of rules for one substance. It says what the substance is, how to prove its identity, how pure it must be and how to measure how much is there [2, 3].
Other parts, called general chapters, describe test methods that many monographs share, such as measuring water content [2, 3].
The big four are the United States Pharmacopeia–National Formulary (USP–NF), the European Pharmacopoeia (Ph. Eur.), the British Pharmacopoeia (BP) and the Japanese Pharmacopoeia (JP) [1]. Each has legal force in its own region [1, 4].
In Australia, the law names three of them, the BP, Ph. Eur. and USP–NF, as “default standards” for medicines [5].
A substance either complies with every requirement of its monograph or it does not have pharmacopoeial quality [6].
The short version
- Monographs set specifications for one substance [2].
- General chapters describe shared methods [2].
- Compliance means meeting the whole monograph [6].
- Australia’s default standards are the BP, Ph. Eur. and USP–NF [5].
What is a pharmacopoeia?
A comparative study by staff of Japan’s medicines agency describes a pharmacopoeia’s core mission as creating and making available public standards that help ensure the quality of drugs [1]. Each major pharmacopoeia has a legal anchor in its region [1, 4, 6, 7]:
| Pharmacopoeia | Published by | Legal standing | Size and edition |
|---|---|---|---|
| USP–NF | United States Pharmacopeial Convention | Used to control the quality of drugs distributed in the US under sections 201(g) and 501(b) of the Federal Food, Drug, and Cosmetic Act [1] | USP 39–NF 34 held 4,597 monographs [1] |
| Ph. Eur. | European Directorate for the Quality of Medicines (EDQM), a directorate of the Council of Europe, under the 1964 Convention on the Elaboration of a European Pharmacopoeia [6] | Legally binding quality standards in its member states; mandatory for marketing authorisations [1, 6] | Ph. Eur. 9.0 held 2,309 monographs [1]; now published online only, currently in its 13th edition [7] |
| BP | British Pharmacopoeia Commission, working with the UK medicines regulator (MHRA) [4] | Has legal status in the UK, alongside the Ph. Eur.; includes all Ph. Eur. monographs and texts [4] | Published every August, legally effective from 1 January of the following year; official standards since 1864 [4] |
| JP | Japan’s Minister responsible for medicines (MHLW), under Article 41 of Japan’s pharmaceuticals and medical devices law [8] | Drugs listed in the JP must meet its standards [8] | First published in 1886; the 19th edition took effect on 10 April 2026 with 2,072 monographs [8] |
The Ph. Eur. platform now releases new texts in numbered issues; texts in Issue 13.3, for example, come into force on 1 July 2027 [7]. Which edition applies on a given date matters when reading a certificate.
What is in a monograph?
The Pharmacopoeial Discussion Group (PDG) describes a typical monograph. It gives a name, a definition, a description and sometimes packaging, labelling and storage statements. It then gives the tests, procedures and acceptance criteria that together make up the specification. For procedures used again and again, a monograph refers to a general chapter [2].
For a synthetic peptide, a USP-focused study of peptide reference materials listed the kinds of tests that appear in peptide monographs and general chapters [3]:
| Monograph element | What it establishes | Typical method or general chapter |
|---|---|---|
| Identification | That the substance is the right peptide | Chromatographic comparison with a reference standard; mass spectrometry or NMR [3] |
| Chirality | That D-amino acids are absent or within limits | Chiral analysis [3] |
| Chromatographic purity | The amount of peptide-related impurities | HPLC [3] |
| Acetic acid; trifluoroacetic acid | Counter-ion content | HPLC, USP 〈503〉 Acetic Acid in Peptides [3, 9] |
| Water | Water content | Karl Fischer titration, USP 〈921〉 [3] |
| Residual solvents | Solvents left from manufacture | Gas chromatography, USP 〈467〉 [3] |
| Inorganic impurities | Non-volatile residue | Residue on ignition, USP 〈281〉 [3] |
| Assay | How much peptide is present | HPLC against a reference standard [3] |
Pharmacopoeias do not always agree. A 2009 review found that peptide specifications for identification, purity and assay differed widely between the Ph. Eur. and the USP, and that peptide monographs were not always consistent even within one pharmacopoeia. The authors proposed a consistent monograph structure [10]. See Peptide Counter-Ions and Karl Fischer Water Content.
General chapters and general monographs
General chapters describe methods and requirements that apply across many substances. Two examples that link to other guides in this library [11]:
- The Ph. Eur. text on residual solvents (5.4) incorporates the ICH Q3C guideline. See Residual Solvents in Peptides.
- For lead, arsenic, cadmium and mercury, the TGA’s guidance on tablets, capsules and pills accepts either USP 〈2232〉 or ICH Q3D. See Elemental Impurities Explained.
The USP–NF also contains a general chapter specific to peptides: 〈1503〉 Quality Attributes of Synthetic Peptide Drug Substances [12].
The Ph. Eur. adds two layers that apply without being cross-referenced in each monograph [6]:
- General Notices apply to all texts and set the rules for reading them.
- General monographs apply to every substance within their scope. The general monograph Substances for pharmaceutical use (2034) applies to all substances for pharmaceutical use, whether or not an individual monograph exists [6]. It took effect in 2002, and the companion general chapter Control of impurities in substances for pharmaceutical use (5.10) adopted the ICH Q3A reporting, identification and qualification thresholds [13].
Are pharmacopoeial methods validated?
According to the Ph. Eur., its test methods have been validated, so the analyst does not need to revalidate them unless the text says otherwise. The user must still assess whether the method is suitable under the actual conditions of use. Alternative methods may be used if they lead to the same pass or fail decision, but the user has to demonstrate that, and the Ph. Eur. method is the reference method in a dispute [6]. See Analytical Method Validation.
Pharmacopoeial reference standards
Many monograph tests compare a sample against a physical reference standard. In a USP study, peptide reference standards were characterised beyond the compendial tests they support. A mass-balance approach assigned a value to the bulk material, and that bulk was then used to assign a value to the material in each vial, with results from several laboratories combined [3]. The BP publishes its own reference standards catalogue (BPCRS) [4]. See Reference Standards Explained.
International harmonisation: the Pharmacopoeial Discussion Group
The PDG was formed in 1989 by the EDQM, the United States Pharmacopeial Convention and the Japanese Pharmacopoeia. The World Health Organization has taken part as an observer since May 2001, and the Indian Pharmacopoeia Commission joined as a member in October 2023 [2], after a one-year pilot that began in September 2022 [14]. The PDG works on excipient monographs and general chapters [2].
The PDG defines a text as harmonised when a substance tested by the harmonised procedure gives the same results and the same accept or reject decision, and the text has become official in all the member pharmacopoeias. When full harmonisation is not possible, it may harmonise “by attribute”, leaving some elements to each pharmacopoeia [2].
Harmonisation is uneven. A 2019 comparison found 625 monographs common to the JP, the Ph. Eur. and the USP–NF [1]. A 2018 review of pyrogen-related tests found the bacterial endotoxins test fully harmonised across the pharmacopoeias, with only minor differences, while the pyrogen test still differed widely [15]. See Endotoxin Testing Explained.
What a pharmacopoeial claim on a research material means
Labels such as “USP grade”, “Ph. Eur.” or “BP” make a specific claim. Three checks make it testable:
- Is there a monograph? A pharmacopoeial claim only has meaning where a monograph for that substance exists in that pharmacopoeia [2].
- Was the whole monograph met? The Ph. Eur. General Notices state that an article is not of pharmacopoeial quality unless it complies with all the requirements stated in its monograph [6].
- Is it documented for the batch? A certificate should list each test performed against compendial requirements, with the acceptance limits and the numerical values found [16].
Using one pharmacopoeial method is a different, narrower claim. “Water by Karl Fischer titration, USP 〈921〉” says how one test was done. It does not say the material meets a monograph.
Worked example: reading “complies with Ph. Eur.”
| What the document shows | What it supports |
|---|---|
| “Complies with Ph. Eur.” with no monograph number or edition | Nothing that can be checked |
| Monograph named, edition stated, every test listed with limit and value | A pharmacopoeial compliance claim for that batch [6, 16] |
| Only an HPLC purity figure, method “per Ph. Eur.” | One test result by a pharmacopoeial method, not monograph compliance |
GMP is a separate question from pharmacopoeial compliance. See GMP Explained.
What this means in Australia
- Default standards. Since 1 July 2009, section 3 of the Therapeutic Goods Act 1989 has defined “default standard” as any of the British Pharmacopoeia, the European Pharmacopoeia and the United States Pharmacopeia–National Formulary [5, 17].
- Which edition. The BP definition includes its online updates in January, April and July, which carry the Ph. Eur. texts taking effect at those times. For the Ph. Eur. and USP–NF, additions, amendments and new editions apply from their effective dates [17].
- Ministerial standards come first. Where a Therapeutic Goods Order sets a requirement that is inconsistent with a default standard, the Order takes precedence. For tablets and capsules, for example, the TGA accepts BP, Ph. Eur. and USP monographs as equivalent default standards [11].
- Research materials. These standards apply to therapeutic goods such as medicines. The TGA has stated that a “research use only” disclaimer does not make supply lawful, change a product’s regulatory status, permit importation, or remove advertising or supply obligations [18].
This is general information, not legal advice. Laws change; check the current Poisons Standard and TGA guidance.
Frequently asked questions
What is a pharmacopoeia?
An official collection of public quality standards for medicines and their ingredients. It contains monographs for individual substances and general chapters describing shared methods [1, 2].
What is a monograph?
The standard for one substance: its name, definition and description, followed by the tests, procedures and acceptance criteria that make up its specification [2].
What is the difference between the USP, Ph. Eur. and BP?
They are published by different bodies and have legal force in different regions. The BP includes all Ph. Eur. monographs and adds UK texts [4]. All three are default standards in Australia [5].
What does “USP grade” mean?
It should mean the batch meets every requirement of the relevant USP–NF monograph. That claim needs a monograph to exist and a certificate showing each test against its limit [6, 16].
What is the Pharmacopoeial Discussion Group?
A group formed in 1989 by the European, Japanese and US pharmacopoeias, joined by the Indian Pharmacopoeia Commission in 2023, that harmonises excipient monographs and general chapters [2].
References
- Kameyama Y, Matsuhama M, Mizumaru C, et al. Comparative study of pharmacopoeias in Japan, Europe, and the United States: toward the further convergence of international pharmacopoeial standards. Chem Pharm Bull (Tokyo). 2019;67(12):1301–1313. doi:10.1248/cpb.c19-00621. PMID: 31787657
- Pharmacopoeial Discussion Group. Statement of harmonisation policy. Revision October 2023. pmda.go.jp. Accessed 25 October 2026.
- McCarthy D, Han Y, Carrick K, et al. Reference standards to support quality of synthetic peptide therapeutics. Pharm Res. 2023;40(6):1317–1328. doi:10.1007/s11095-023-03493-1. PMID: 36949371
- British Pharmacopoeia. What is the BP? pharmacopoeia.com. Accessed 25 October 2026.
- Therapeutic Goods Administration. Pharmacopoeias. tga.gov.au. Accessed 25 October 2026.
- McMath A (European Directorate for the Quality of Medicines). The European Pharmacopoeia and certificates of suitability (CEP). Presentation. European Medicines Agency. ema.europa.eu. Accessed 25 October 2026.
- European Directorate for the Quality of Medicines. European Pharmacopoeia Online. pheur.edqm.eu. Accessed 25 October 2026.
- Pharmaceuticals and Medical Devices Agency (Japan). JP history and legal status. pmda.go.jp. Accessed 25 October 2026.
- United States Pharmacopeial Convention. 〈503〉 Acetic acid in peptides. In: United States Pharmacopeia–National Formulary. doi:10.31003/uspnf_m2427_01_01. Accessed 25 October 2026.
- Vergote V, Burvenich C, Van de Wiele C, De Spiegeleer B. Quality specifications for peptide drugs: a regulatory-pharmaceutical approach. J Pept Sci. 2009;15(11):697–710. doi:10.1002/psc.1167. PMID: 19750489
- Therapeutic Goods Administration. Complying with quality standards for tablets, capsules and pills (TGO 101). May 2025. tga.gov.au. Accessed 25 October 2026.
- United States Pharmacopeial Convention. 〈1503〉 Quality attributes of synthetic peptide drug substances. In: United States Pharmacopeia–National Formulary. doi:10.31003/uspnf_m12935_04_01. Accessed 25 October 2026.
- European Medicines Agency. Position paper on control of impurities of pharmacopoeial substances: compliance with the European Pharmacopoeia general monograph “Substances for pharmaceutical use” and general chapter “Control of impurities in substances for pharmaceutical use”. EMEA/CVMP/059/04. 2004. ema.europa.eu. Accessed 25 October 2026.
- Jadaun GPS, Rastogi S, Kumar A, et al. Ensuring the quality of medicines in India: an update on the development, modernization, and harmonization of drug standards in the Indian Pharmacopoeia. Saudi Pharm J. 2023;31(12):101825. doi:10.1016/j.jsps.2023.101825. PMID: 37965488
- Franco E, Garcia-Recio V, Jiménez P, et al. Endotoxins from a pharmacopoeial point of view. Toxins (Basel). 2018;10(8):331. doi:10.3390/toxins10080331. PMID: 30115887
- International Council for Harmonisation. ICH Q7: Good manufacturing practice guide for active pharmaceutical ingredients. 2000. database.ich.org. Accessed 25 October 2026.
- Therapeutic Goods Administration. Questions and answers relating to the additional default standards legislation. tga.gov.au. Accessed 25 October 2026.
- Therapeutic Goods Administration. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. Safety advisory, 13 April 2026. tga.gov.au. Accessed 25 October 2026.
